Danijela Gnjidic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6895181/publications.pdf

Version: 2024-02-01

117625 79698 5,826 128 34 73 citations g-index h-index papers 129 129 129 5901 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Barriers, facilitators, and resources to opioid deprescribing in primary care: experiences of general practitioners in Australia. Pain, 2022, 163, e518-e526.	4.2	19
2	Medication therapy in older adults. , 2022, , 479-498.		0
3	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality and Safety, 2022, 31, 179-190.	3.7	6
4	Preclinical frailty assessments: Phenotype and frailty index identify frailty in different mice and are variably affected by chronic medications. Experimental Gerontology, 2022, 161, 111700.	2.8	8
5	Can we improve patient outcomes through using evidence-based opioid deprescribing guidelines to reduce opioid use?. Pain, 2022, 163, e382-e382.	4.2	O
6	Patient risk factors for opioidâ€related adverse drug events in hospitalized patients: A systematic review. Pharmacotherapy, 2022, 42, 194-215.	2.6	6
7	Opioid-related adverse drug events in surgical patients: risk factors and association with clinical outcomes. Expert Opinion on Drug Safety, 2022, 21, 1211-1223.	2.4	2
8	Comparing Effects of Polypharmacy on Inflammatory Profiles in Older Adults and Mice: Implications for Translational Aging Research. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 1295-1303.	3.6	8
9	The Prevalence of Frailty Among Older Adults Living With Dementia: A Systematic Review. Journal of the American Medical Directors Association, 2022, 23, 1807-1814.	2.5	11
10	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	3.2	2
11	Development of a tool to evaluate medication management guidance provided to carers of people living with dementia at hospital discharge: a mixed methods study. BMJ Open, 2022, 12, e058237.	1.9	1
12	Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis. BMJ Quality and Safety, 2021, 30, 133-140.	3.7	27
13	The utility of a computerised clinical decision support system intervention in home medicines review: A mixed-methods process evaluation. Research in Social and Administrative Pharmacy, 2021, 17, 715-722.	3.0	12
14	A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVIDâ€19 (SARSâ€COVâ€2) treatments. British Journal of Clinical Pharmacology, 2021, 87, 707-711.	. 2.4	20
15	Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review. British Journal of Clinical Pharmacology, 2021, 87, 375-385.	2.4	15
16	Quantifying cumulative anticholinergic and sedative drug load among US Medicare Beneficiaries. Pharmacoepidemiology and Drug Safety, 2021, 30, 144-156.	1.9	4
17	Impact of the Goalâ€directed Medication Review Electronic Decision Support System on Drug Burden Index: A clusterâ€randomised clinical trial in primary care. British Journal of Clinical Pharmacology, 2021, 87, 1499-1511.	2.4	26
18	Deprescribing: What do we know, and where to next?. British Journal of Clinical Pharmacology, 2021, 87, 722-724.	2.4	13

#	Article	IF	CITATIONS
19	Pain, Complex Chronic Conditions and Potential Inappropriate Medication in People with Dementia. Lessons Learnt for Pain Treatment Plans Utilizing Data from the Veteran Health Administration. Brain Sciences, 2021, 11, 86.	2.3	6
20	Interventions at Hospital Discharge to Guide Caregivers in Medication Management for People Living with Dementia: a Systematic Review. Journal of General Internal Medicine, 2021, 36, 1371-1379.	2.6	11
21	Caregivers' experiences of medication management advice for people living with dementia at discharge. Journal of Evaluation in Clinical Practice, 2021, 27, 1252-1261.	1.8	12
22	"The lesser of two evils― a framework analysis of consumers' perspectives on opioid deprescribing and the development of opioid deprescribing guidelines. Pain, 2021, 162, 2686-2692.	4.2	12
23	Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1748-1756.	3.6	13
24	Effects of anticholinergic and sedative medication use on fractures: A <scp>selfâ€eontrolled</scp> design study. Journal of the American Geriatrics Society, 2021, 69, 3212-3224.	2.6	8
25	Tools to evaluate medication management for caregivers of people living with dementia: A systematic review. Health Expectations, 2021, 24, 1570-1581.	2.6	7
26	The value of deprescribing in older adults with dementia: a narrative review. Expert Review of Clinical Pharmacology, 2021, 14, 1367-1382.	3.1	9
27	Development and validation of a frailty index based on data routinely collected across multiple domains in NSW hospitals. Australasian Journal on Ageing, 2021, 40, 184-194.	0.9	5
28	Deprescribing paracetamol in pain conditions: A scoping review. Research in Social and Administrative Pharmacy, 2021, , .	3.0	3
29	Long-Term Exposure to Anticholinergic and Sedative Medications and Cognitive and Physical Function in Later Life. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 357-365.	3.6	29
30	Effectiveness of interventions on the appropriate use of opioids for noncancer pain among hospital inpatients: A systematic review. British Journal of Clinical Pharmacology, 2020, 86, 210-243.	2.4	13
31	The Effectiveness of Stewardship Interventions to Reduce the Prescribing of Extended-Release Opioids for Acute Pain: A Systematic Review. Pain Medicine, 2020, 21, 2401-2411.	1.9	3
32	Effect of an electronic medical record design modification on laxative co-prescribing among hospitalised patients taking opioids: A before-and-after study. International Journal of Medical Informatics, 2020, 140, 104172.	3.3	1
33	Withdrawal of antihypertensive drugs in older people. The Cochrane Library, 2020, 2020, CD012572.	2.8	31
34	Implementation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS) \hat{A} © into home medicines review: a protocol for a cluster-randomised clinical trial in older adults. BMC Geriatrics, 2020, 20, 51.	2.7	15
35	A systems approach to identifying the challenges of implementing deprescribing in older adults across different health-care settings and countries: a narrative review. Expert Review of Clinical Pharmacology, 2020, 13, 233-245.	3.1	58
36	Adverse drug reactions due to opioid analgesic use in New South Wales, Australia: a spatial-temporal analysis. BMC Pharmacology & Empty 2019, 20, 55.	2.4	1

#	Article	IF	CITATIONS
37	The impact of in hospital patient-education intervention on older people's attitudes and intention to have their benzodiazepines deprescribed: a feasibility study. Therapeutic Advances in Drug Safety, 2019, 10, 204209861881656.	2.4	18
38	Health professionals' and researchers' opinions on conducting clinical deprescribing trials. Pharmacology Research and Perspectives, 2019, 7, e00476.	2.4	9
39	Platinum drugs in the Australian cancer chemotherapy healthcare setting: Is it worthwhile for chemists to continue to develop platinums?. Inorganica Chimica Acta, 2019, 492, 177-181.	2.4	21
40	Availability and readability of patient education materials for deprescribing: An environmental scan. British Journal of Clinical Pharmacology, 2019, 85, 1396-1406.	2.4	49
41	Integration of an electronic Drug Burden Index risk assessment tool into Home Medicines Reviews: deprescribing anticholinergic and sedative medications. Therapeutic Advances in Drug Safety, 2019, 10, 204209861983247.	2.4	13
42	Patterns of high-risk prescribing and other factors in relation to receipt of a home medicines review: a prospective cohort investigation among adults aged 45 years and over in Australia. BMJ Open, 2019, 9, e027305.	1.9	7
43	Investigation of opioid prescribing in the postoperative setting among opioidâ€naÃ⁻ve surgical patients: a 6â€month observational study. Journal of Pharmacy Practice and Research, 2019, 49, 58-61.	0.8	5
44	Development of consumer information leaflets for deprescribing in older hospital inpatients: a mixed-methods study. BMJ Open, 2019, 9, e033303.	1.9	13
45	Pharmacoepidemiology in older people: Purposes and future directions. Therapie, 2019, 74, 325-332.	1.0	9
46	The Feasibility of Using N-Of-1 Trials to Investigate Deprescribing in Older Adults with Dementia: A Pilot Study. Healthcare (Switzerland), 2019, 7, 161.	2.0	9
47	Trends in adverse drug reactionâ€related hospitalisations over 13 years in New South Wales, Australia. Internal Medicine Journal, 2019, 49, 84-93.	0.8	16
48	Deprescribing: the emerging evidence for and the practice of the â€~geriatrician's salute'. Age and Ageing, 2018, 47, 638-640.	1.6	18
49	Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. International Psychogeriatrics, 2018, 30, 1477-1487.	1.0	43
50	The Impact of Dementia Diagnosis on Patterns of Potentially Inappropriate Medication Use Among Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1410-1417.	3.6	27
51	Association rules method and big data: Evaluating frequent medication combinations associated with fractures in older adults. Pharmacoepidemiology and Drug Safety, 2018, 27, 1123-1130.	1.9	8
52	Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review. Journal of Alzheimer's Disease, 2018, 61, 1639-1652.	2.6	63
53	Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 1-10.	3.7	19
54	Pharmacotherapy. Practical Issues in Geriatrics, 2018, , 219-235.	0.8	4

#	Article	IF	CITATIONS
55	Impact of Deprescribing Interventions in Older Hospitalised Patients on Prescribing and Clinical Outcomes: A Systematic Review of Randomised Trials. Drugs and Aging, 2018, 35, 303-319.	2.7	135
56	N-of-1 trials for assessing the effects of deprescribing medications on short-term clinical outcomes in older adults: a systematic review. Journal of Clinical Epidemiology, 2018, 93, 112-119.	5.0	16
57	Frailty, Polypharmacy, and Health Outcomes in Older Adults: TheÂFrailty and Dependence in Albacete Study. Journal of the American Medical Directors Association, 2018, 19, 46-52.	2.5	98
58	Clinical practice guidelines for older people with multimorbidity and life-limiting illness: what are the implications for deprescribing?. Therapeutic Advances in Drug Safety, 2018, 9, 619-630.	2.4	18
59	Patterns of platinum drug use in an acute care setting: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1561-1568.	2.5	22
60	Challenges and innovations of delivering medicines to older adults. Advanced Drug Delivery Reviews, 2018, 135, 97-105.	13.7	14
61	Assessing medication burden and polypharmacy: finding the perfect measure. Expert Review of Clinical Pharmacology, 2017, 10, 345-347.	3.1	41
62	Complementing or expanding on existing areas of research expertise: The importance of attending and organising conferences in specific clinical areas. Research in Social and Administrative Pharmacy, 2017, 13, 656-657.	3.0	0
63	A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. European Journal of Clinical Pharmacology, 2017, 73, 927-935.	1.9	114
64	A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland. Drugs and Aging, 2017, 34, 55-65.	2.7	14
65	Drug Burden Index and change in cognition over time in community-dwelling older men: the CHAMP study. Annals of Medicine, 2017, 49, 157-164.	3 . 8	23
66	Anticholinergic burden: considerations for older adults. Journal of Pharmacy Practice and Research, 2017, 47, 67-77.	0.8	30
67	Polypharmacy in older adults: Association Rule and Frequent-Set Analysis to evaluate concomitant medication use. Pharmacological Research, 2017, 116, 39-44.	7.1	16
68	Guidelineâ€Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions. Journal of the American Geriatrics Society, 2017, 65, 2619-2626.	2.6	5
69	Hospital pharmacists' beliefs about optimising statin therapy in older inpatients. Journal of Pharmacy Practice and Research, 2017, 47, 223-227.	0.8	3
70	Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 259-265.	3.6	14
71	Ascertainment of self-reported prescription medication use compared with pharmaceutical claims data. Public Health Research and Practice, 2017, 27, .	1.5	24
72	Prescribing for frail older people. Australian Prescriber, 2017, 40, 174-178.	1.0	50

#	Article	IF	CITATIONS
73	Education and Assessment of Pharmacists on the Use of the Drug Burden Index in Older Adults Using a Continuing Professional Development Education Method. American Journal of Pharmaceutical Education, 2016, 80, 63.	2.1	11
74	Effects of Changes in Number of Medications and Drug Burden Index Exposure on Transitions Between Frailty States and Death: The Concord Health and Ageing in Men Project Cohort Study. Journal of the American Geriatrics Society, 2016, 64, 89-95.	2.6	92
75	Statin Therapy and Dementia in Older Adults: Role of Disease Severity and Multimorbidity. Journal of the American Geriatrics Society, 2016, 64, 223-224.	2.6	9
76	Health Care Practitioners' Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. Annals of Pharmacotherapy, 2016, 50, 625-636.	1.9	76
77	Response to Timo E. Strandberg. Journal of the American Geriatrics Society, 2016, 64, 1927-1928.	2.6	0
78	Prevalence of statin-drug interactions in older people: a systematic review. European Journal of Clinical Pharmacology, 2016, 72, 513-521.	1.9	27
79	Development, validation and evaluation of an electronic pharmacological tool: The Drug Burden Index Calculator©. Research in Social and Administrative Pharmacy, 2016, 12, 865-875.	3.0	29
80	â€Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. International Journal of Cardiology, 2016, 203, 746-752.	1.7	38
81	Association Rules Analysis of Comorbidity and Multimorbidity: The Concord Health and Aging in Men Project. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 625-631.	3.6	89
82	Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 171-188.	0.6	0
83	De-adoption and its 43 related terms: harmonizing low-value care terminology. BMC Medicine, 2015, 13, 273.	5.5	39
84	Measuring anticholinergic drug exposure in older communityâ€dwelling Australian men: a comparison of four different measures. British Journal of Clinical Pharmacology, 2015, 80, 1169-1175.	2.4	46
85	A systematic review of the emerging definition of †deprescribing' with network analysis: implications for future research and clinical practice British Journal of Clinical Pharmacology, 2015, 80, 1254-1268.	2.4	461
86	Anticholinergic burden in older women: not seeing the wood for the trees?. Medical Journal of Australia, 2015, 202, 91-94.	1.7	25
87	Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. International Journal of Clinical Pharmacy, 2015, 37, 949-957.	2.1	86
88	Ischemic heart disease, prescription of optimal medical therapy and geriatric syndromes in community-dwelling older men: A population-based study. International Journal of Cardiology, 2015, 192, 49-55.	1.7	27
89	Reducing Inappropriate Polypharmacy. JAMA Internal Medicine, 2015, 175, 827.	5.1	1,054
90	Prevalence of Potential and Clinically Relevant Statin–Drug Interactions in Frail and Robust Older Inpatients. Drugs and Aging, 2015, 32, 849-856.	2.7	25

#	Article	IF	Citations
91	Statin Therapy and Cognition in Older People: What is the Evidence?. Current Clinical Pharmacology, 2015, 10, 185-193.	0.6	10
92	Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study. Public Health Research and Practice, 2015, 25, e2521518.	1.5	1
93	Drug Burden Index in older adults: theoretical and practical issues. Clinical Interventions in Aging, 2014, 9, 1503.	2.9	113
94	Modifications to the Drug Burden Index Calculation May Limit Interpretation of its Association with Clinical Outcomes in Older Adults. Neurocritical Care, 2014, 21, 365-366.	2.4	0
95	Analgesic use, pain and daytime sedation in people with and without dementia in aged care facilities: a cross-sectional, multisite, epidemiological study protocol. BMJ Open, 2014, 4, e005757-e005757.	1.9	34
96	Assessing the harms of polypharmacy requires careful interpretation and consistent definitions. British Journal of Clinical Pharmacology, 2014, 78, 670-671.	2.4	9
97	Discontinuing drug treatments. BMJ, The, 2014, 349, g7013-g7013.	6.0	40
98	Optimizing the Impact of Drugs on Symptom Burden in Older People With Multimorbidity at the End of Life. JAMA Internal Medicine, 2014, 174, 636.	5.1	1
99	Sedative load and functional outcomes in communityâ€dwelling older Australian men: the <scp>CHAMP</scp> study. Fundamental and Clinical Pharmacology, 2014, 28, 10-19.	1.9	14
100	Prevalence and Impact of Fall-Risk-Increasing Drugs, Polypharmacy, and Drug–Drug Interactions in Robust Versus Frail Hospitalised Falls Patients: A Prospective Cohort Study. Drugs and Aging, 2014, 31, 225-232.	2.7	119
101	Nonsteroidal anti-inflammatory drugs (NSAIDs) in older people: Prescribing patterns according to pain prevalence and adherence to clinical guidelines. Pain, 2014, 155, 1814-1820.	4.2	20
102	Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer's Disease: A National Population Cohort Study. PLoS ONE, 2014, 9, e83224.	2.5	78
103	High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 2013, 13, 115.	2.9	32
104	Optimal cutoff of polypharmacy and outcomes - reply. Journal of Clinical Epidemiology, 2013, 66, 465-466.	5.0	2
105	Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open, 2013, 3, e002333.	1.9	44
106	Understanding Drug Effects in Older People: The Role of Pharmacology. JAMA Internal Medicine, 2013, 173, 1930.	5.1	0
107	Clinical implications from drug–drug and drug–disease interactions in older people. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 320-325.	1.9	50
108	Reâ€Evaluating Psychotropic Drug Use Across Care Settings. Journal of the American Geriatrics Society, 2013, 61, 1640-1641.	2.6	0

#	Article	IF	Citations
109	Statins in older adults. Australian Prescriber, 2013, 36, 79-82.	1.0	30
110	Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 181-188.	3.6	44
111	Drug Burden Index associated with function in community-dwelling older people in Finland: A cross-sectional study. Annals of Medicine, 2012, 44, 458-467.	3.8	58
112	Sedative Load Among Community-Dwelling People Aged 75 Years or Older. Journal of Clinical Psychopharmacology, 2012, 32, 218-224.	1.4	28
113	Effects of Drug Burden Index on Cognitive Function in Older Men. Journal of Clinical Psychopharmacology, 2012, 32, 273-277.	1.4	47
114	Drug Burden Index and Beers Criteria: Impact on Functional Outcomes in Older People Living in Selfã€Care Retirement Villages. Journal of Clinical Pharmacology, 2012, 52, 258-265.	2.0	55
115	High-risk prescribing in older people: more harm than good?. Aging Health, 2012, 8, 325-327.	0.3	6
116	Deprescribing Trials: Methods to Reduce Polypharmacy and the Impact on Prescribing and Clinical Outcomes. Clinics in Geriatric Medicine, 2012, 28, 237-253.	2.6	173
117	Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology, 2012, 65, 989-995.	5.0	891
118	Drug Burden Index and Hospitalization among Community-Dwelling Older People. Drugs and Aging, 2012, 29, 395-404.	2.7	40
119	Mild Cognitive Impairment Predicts Institutionalization among Older Men: A Population-Based Cohort Study. PLoS ONE, 2012, 7, e46061.	2.5	35
120	Reducing Drugs in Older Adults Is More. Archives of Internal Medicine, 2011, 171, 868.	3.8	1
121	Use of PPIs Are Not Associated With Mortality in Institutionalized Older People. Archives of Internal Medicine, 2011, 171, 866.	3.8	6
122	Muscle Strength and Sedative Load in Community-Dwelling People Aged 75 Years and Older: A Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 1384-1392.	3.6	19
123	Deprescribing. Australian Prescriber, 2011, 34, 182-185.	1.0	47
124	Use of potentially inappropriate medications in the care of frail older people. Aging Health, 2010, 6, 705-716.	0.3	22
125	A Pilot Randomized Clinical Trial Utilizing the Drug Burden Index to Reduce Exposure to Anticholinergic and Sedative Medications in Older People. Annals of Pharmacotherapy, 2010, 44, 1725-1732.	1.9	64
126	Drug Burden Index and physical function in older Australian men. British Journal of Clinical Pharmacology, 2009, 68, 97-105.	2.4	137

#	Article	IF	CITATIONS
127	Age and opioid analgesia in an acute hospital population. Age and Ageing, 2008, 37, 699-702.	1.6	14
128	Withdrawal of antihypertensive drugs in older people. The Cochrane Library, 0, , .	2.8	3